The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Damayanti Kerai - HSBC - Analyst
: My first question is on your upcoming launch of Stelara biosimilars. So a few weeks away from now, you'll be launching. So just --
Question: Damayanti Kerai - HSBC - Analyst
: Hello?
Question: Damayanti Kerai - HSBC - Analyst
: Okay. My question is on Stelara biosimilar, which you'll be launching soon. So just want to understand, based on your discussion with channel
partners, what kind of sense you are getting for the potential uptake of this product? Because we understand this is a Part D product, and what we
heard from J&J is that they are expecting similar dynamics to play out, what we have seen in case of adalimumab, Humira biosimilar, plus any
change from the Part D redesign. So just want to get some sense what you have heard or any like feedback, which you might have got from the
channel partners?
Question: Damayanti Kerai - HSBC - Analyst
: Hello. My second question is on your existing biosimilars, where you continue to see market share gain. However, when we look at the profitability
side, it's not in line with, I think, the kind of pickup seen on the revenue side. So can you just comment like whether most of the market share gain
is on low realization channels? And how should we look at like further scope of increasing market share for these existing products?
Question: Damayanti Kerai - HSBC - Analyst
: I have more questions, I'll get back in the queue. .
Question: Damayanti Kerai - HSBC - Analyst
: This is at consol level, right, or at the BBL level?
Question: Surya Patra - PhillipCapital (India) Private Limited - Analyst
: Yes.
Question: Surya Patra - PhillipCapital (India) Private Limited - Analyst
: Okay. Is it now audible, sir? .
Question: Surya Patra - PhillipCapital (India) Private Limited - Analyst
: Yes. My first question is on the biosimilar opportunities only. Could you give some sense of what is the kind of preparedness that you have done
about ustekinumab? And what is the likelihood or what is your expectation on that front?
And the second is on the (inaudible) What is the launch expectation that you are having for this molecule for U.S. market. So this is the first 2
questions.
Question: Surya Patra - PhillipCapital (India) Private Limited - Analyst
: And the denosumab launch time line. So is it an FY '26 opportunity in the U.S. for you?
Question: Surya Patra - PhillipCapital (India) Private Limited - Analyst
: My second question on the generic business. So we have got now the China approval for tacrolimus. Simultaneously that we have got now this
Cranbury facility ready for U.S. manufacturing. So how important these 2 developments are for our generic business progress?
| 
